Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.71)
# 765
Out of 5,022 analysts
420
Total ratings
44.9%
Success rate
16.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCGN Ocugen | Maintained: Buy | $11 | $1.09 | +909.17% | 8 | Sep 30, 2026 | |
| PHAR Pharming Group | Maintained: Buy | $38 | $10.01 | +279.62% | 6 | Sep 30, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $13.70 | +45.99% | 31 | Sep 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Hold | $442 | $526.73 | -16.09% | 40 | Sep 23, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $37 → $39 | $15.32 | +154.57% | 27 | Sep 18, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | $78 | $24.52 | +218.11% | 7 | Sep 9, 2026 | |
| BLTE Belite Bio | Initiated Coverage: Buy | $303 | $166.51 | +81.98% | 1 | Sep 4, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $114 | $59.87 | +90.41% | 23 | Aug 31, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $429 | $254.07 | +68.85% | 37 | Aug 28, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $104 → $106 | $65.97 | +60.68% | 2 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.52 | +1,438.46% | 18 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 → $166 | $28.39 | +484.71% | 6 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.59 | +286.10% | 23 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $4.99 | +240.68% | 26 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 | $12.03 | +307.32% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.5931 | +743.03% | 25 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $227 → $232 | $139.00 | +66.91% | 22 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $151 → $154 | $95.71 | +60.90% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 | $3.64 | +1,081.32% | 15 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $4.63 | +396.76% | 15 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $83 → $114 | $335.06 | n/a | 5 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $18.64 | n/a | 2 | Sep 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $151.28 | n/a | 4 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $123.20 | n/a | 1 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $24.51 | n/a | 4 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $27 | $87.54 | n/a | 2 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 | $0.14 | n/a | 5 | Nov 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $56.00 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $2.59 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $23.34 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $16 | $1.21 | n/a | 5 | May 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.9605 | n/a | 2 | Jan 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.34 | n/a | 1 | May 13, 2014 |
Ocugen
Sep 30, 2026
Maintained: Buy
Price Target: $11
Current: $1.09
Upside: +909.17%
Pharming Group
Sep 30, 2026
Maintained: Buy
Price Target: $38
Current: $10.01
Upside: +279.62%
Arcturus Therapeutics Holdings
Sep 24, 2026
Reiterated: Buy
Price Target: $20
Current: $13.70
Upside: +45.99%
Vertex Pharmaceuticals
Sep 23, 2026
Reiterated: Hold
Price Target: $442
Current: $526.73
Upside: -16.09%
Ultragenyx Pharmaceutical
Sep 18, 2026
Reiterated: Buy
Price Target: $37 → $39
Current: $15.32
Upside: +154.57%
Beam Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $78
Current: $24.52
Upside: +218.11%
Belite Bio
Sep 4, 2026
Initiated Coverage: Buy
Price Target: $303
Current: $166.51
Upside: +81.98%
BioMarin Pharmaceutical
Aug 31, 2026
Reiterated: Buy
Price Target: $114
Current: $59.87
Upside: +90.41%
Alnylam Pharmaceuticals
Aug 28, 2026
Reiterated: Buy
Price Target: $429
Current: $254.07
Upside: +68.85%
BridgeBio Pharma
Aug 12, 2026
Reiterated: Buy
Price Target: $104 → $106
Current: $65.97
Upside: +60.68%
Aug 12, 2026
Reiterated: Buy
Price Target: $8
Current: $0.52
Upside: +1,438.46%
Aug 12, 2026
Reiterated: Buy
Price Target: $180 → $166
Current: $28.39
Upside: +484.71%
Aug 12, 2026
Reiterated: Buy
Price Target: $10
Current: $2.59
Upside: +286.10%
Aug 11, 2026
Reiterated: Buy
Price Target: $17
Current: $4.99
Upside: +240.68%
Aug 6, 2026
Reiterated: Buy
Price Target: $49
Current: $12.03
Upside: +307.32%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.5931
Upside: +743.03%
Aug 5, 2026
Reiterated: Buy
Price Target: $227 → $232
Current: $139.00
Upside: +66.91%
Aug 5, 2026
Reiterated: Buy
Price Target: $151 → $154
Current: $95.71
Upside: +60.90%
May 19, 2026
Reiterated: Buy
Price Target: $43
Current: $3.64
Upside: +1,081.32%
Apr 21, 2026
Reiterated: Buy
Price Target: $23
Current: $4.63
Upside: +396.76%
Feb 28, 2022
Reiterated: Buy
Price Target: $83 → $114
Current: $335.06
Upside: n/a
Sep 15, 2021
Upgraded: Buy
Price Target: n/a
Current: $18.64
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $151.28
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $123.20
Upside: n/a
Jun 25, 2020
Reiterated: Hold
Price Target: n/a
Current: $24.51
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $18 → $27
Current: $87.54
Upside: n/a
Nov 9, 2018
Downgraded: Hold
Price Target: $18
Current: $0.14
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $56.00
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $2.59
Upside: n/a
Oct 9, 2018
Initiated Coverage: Buy
Price Target: $35
Current: $23.34
Upside: n/a
May 4, 2017
Reiterated: Buy
Price Target: $19 → $16
Current: $1.21
Upside: n/a
Jan 11, 2017
Reiterated: Hold
Price Target: n/a
Current: $0.9605
Upside: n/a
May 13, 2014
Reiterated: Hold
Price Target: n/a
Current: $3.34
Upside: n/a